The Study Of Lung Adenocarcinoma Serum Biomarkers Selected By Surface-enhanced Laser Desorption Lonization Spectrometry

Objective To select specifical biomarkers in serum from lung adenocarcinoma patients using surface-enhanced laser desorption and ionization time of flight mass spectrometry (SELDI-TOF-MS) ProteinChip technology.Methods Serum samples from 71 lung adenocarcinoma patients, 71 healthy volunteers with matched gender, age and history of smoking were analyzed using WCX2 PoteinChip to select potentially biomarkers. 71 lung adenocarcinoma patients received surgery treatment, compare the serum protein spectrum before and 7 days after the operation using SELDI-TOF-MS. Examine the serum protein spectrum of 20 lung adenocarcinoma patients who were followed till 9 months after the operation.Results Five highly expressed potential biomarkers were identified with the relative molecular weights of 4047.79±1.60, 4203.99±1.91, 4959.81±2.13, 5329.30±2.55 and 7760.12±4.11. The sensitivity for diagnosing lung adenocarcinoma was 90.41%, 78.08%, 50.68%, 57.53% , 72.60%; and specificity was 97.06%, 93.44%, 71.15%, 76.36%, 94.92%, when the critical point was made 2.0. The serum protein spectrum before and 7 days, 9 months after the operation variate among individualsConclusions SELDI-TOF-MS ProteinChip technology is a quick, easy, convenient, and high-throughput analyzing method capable of selecting several relatively specific , potential biomarkers from the serum of lung adenocarcinoma patients and may have attracting clinic value.